8 Weeks
5 mg Vial- VialsCagrilintide mg vials
- 4
- U-100 Syringesone sterile syringe per dose
- 12
- BAC Water30 mL multi-dose vials
- 1
- Alcohol Padsvial stopper + skin prep
- 20
8 total doses over 8 weeks
Long-Acting Acylated Amylin Analog (NN9838)
A long-acting acylated amylin and calcitonin receptor dual agonist (DACRA) designed for once-weekly subcutaneous administration to promote satiety, slow gastric emptying, and enhance weight loss.
Cagrilintide Reference VialSelect your vial strength to update all reference concentrations, dosage tables, and syringe draws on this page.
Arithmetic summary: Reconstituting a 5 mg Cagrilintide vial with 1 mL of bacteriostatic water yields 5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 500 mcg.
Cagrilintide · 5 mg VialArithmetic summary: Reconstituting a 10 mg Cagrilintide vial with 2 mL of bacteriostatic water yields 5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 500 mcg.
Cagrilintide · 10 mg VialSelect a row to preview the draw on the syringe. Values are reference figures from the literature, not medical advice.
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce weekly · Weeks 1–2 | 600 mcg | 0.12 | 12 | 8 |
| StandardOnce weekly · Weeks 3–4 | 1.2 mg | 0.24 | 24 | 4 |
| TargetOnce weekly · Weeks 5–8+ | 2.4 mg | 0.48 | 48 | 2 |
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce weekly · Weeks 1–2 | 600 mcg | 0.12 | 12 | 16 |
| StandardOnce weekly · Weeks 3–4 | 1.2 mg | 0.24 | 24 | 8 |
| TargetOnce weekly · Weeks 5–8+ | 2.4 mg | 0.48 | 48 | 4 |
U-100 syringe drawn to 12 units (0.12 mL), 600 mcg.
Dose exceeds this syringe's capacity. Choose a larger syringe or reduce the diluent volume.
Click any dosing tier row above to preview that exact draw on the U-100 syringe scale.
Four steps, in order. Work on a clean surface with washed hands and swab every vial top with alcohol first.
Step 01Draw 1 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe. Use bacteriostatic, not plain sterile water, so the multi-dose vial stays preserved between draws.
Step 02Pierce the stopper and angle the needle at 45° so the water runs slowly down the inside glass wall. Never spray directly onto the lyophilized puck: the jet foams the solution and can denature fragile peptide chains.
Step 03Roll the vial gently between your fingers or swirl in a slow circle until the liquid is 100% clear with no undissolved particles. Shaking shears peptide bonds and traps air bubbles; if it clouds, let it rest in the fridge for 15 minutes.
Step 04Write the reconstitution date and concentration on the vial. Refrigerate upright at 2–8 °C (36–46 °F), protected from light, and use within 28–30 days. Do not freeze the reconstituted liquid.
Convert a lyophilized peptide vial amount and bacteriostatic water volume into a reconstitution concentration, then translate your protocol dose and schedule into exact U-100 syringe units and multi-week vial supplies.
Enter the peptide amount in the vial and the volume of bacteriostatic or sterile water you plan to add.
Concentration
How much peptide each mL of solution contains after mixing.
5 mg/mL
Enter the dose from your protocol, select your dosing schedule, and pick the insulin syringe you are using.
100-unit (1 mL): marks every 2 units. Standard barrel for draws up to 100 units.
Draw to
Pull plunger seal to line 5
Volume
0.05 mL
Delivers 250 mcg
Doses per vial
20
Lasts 20 days (Once daily)
4-Week Schedule Supply
2 vials
28 doses · 2.0 mL BAC water
| Duration | Total Peptide | Vials Required | U-100 Syringes | BAC Water |
|---|
For educational and research calculations only. Always confirm calculations independently before use.
Plan vials, U-100 insulin syringes, bacteriostatic water, and sterile alcohol prep pads by protocol duration.

Cagrilintide Vials (5 mg each):
U-100 Insulin Syringes & Alcohol Pads:
8 total doses over 8 weeks
12 total doses over 12 weeks
16 total doses over 16 weeks

Cagrilintide Vials (10 mg each):
U-100 Insulin Syringes & Alcohol Pads:
8 total doses over 8 weeks
12 total doses over 12 weeks
16 total doses over 16 weeks
Synergistic Protocols
Common research and clinical combinations pairing Cagrilintide with complementary pathways.
Supports gastric mucosal integrity and reduces GI side effects during GLP-1/GIP titration while protecting tendons and connective tissue during rapid weight loss.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| Cagrilintide | Per weekly titration schedule | Once weekly SubQ |
| BPC-157 | 250–500 mcg daily | Daily SubQ or oral arginate salt |
Stacking Note: Pair with 1.6g/kg daily protein intake and resistance training 3x/week to preserve skeletal muscle mass.
Prevents the 20–30% lean-mass loss commonly seen with caloric restriction alone by maintaining physiological GH/IGF-1 signaling.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| Cagrilintide | Weekly maintenance or titration dose | Once weekly SubQ |
| Tesamorelin or CJC-1295/Ipamorelin | 1 mg Tesamorelin or 100/100 mcg CJC/Ipa | Nightly fasted SubQ (5 days/week) |
Stacking Note: Inject in separate abdominal quadrants and keep evening GH secretagogue dose at least 2 hours after dinner.
Combines appetite/glycemic regulation with mitochondrial AMPK activation (MOTS-c) and NNMT inhibition (5-Amino-1MQ) to counter metabolic adaptation.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| MOTS-c | 5 mg 2–3x weekly | Morning pre-exercise SubQ |
| 5-Amino-1MQ | 50–100 mg daily | Morning capsule or SubQ |
Stacking Note: Administer MOTS-c and 5-Amino-1MQ in the morning to align with circadian NAD+/SIRT1 activity.
Rotate sites with every injection so no single area is used twice in a row. Swab with alcohol and let it dry for 10 seconds before injecting.

Zone 01
Abdomen
≥ 2 in away from navel
Zone 02
Outer Thigh
Middle third, anterior-lateral
Zone 03
Upper Arm
Posterior / outer tricep pad
90° · 4–8 mm (31 G) short needle
Standard U-100 insulin syringe: pinch a light fold and insert straight in at 90°.
45° · 12.7 mm (1/2 in) needle
Longer needle or leaner area: pinch a 1-inch fold and enter at 45° into fat.
Aseptic Injection Checklist
• Use a brand-new sterile U-100 syringe for every draw (never reuse needles).
• Swab both the vial rubber stopper and injection site with 70% isopropyl alcohol and let dry.
• Rotate clockwise around the abdomen or alternate left/right thigh to prevent lipohypertrophy.
Lyophilized Powder (Unmixed)
Freezer −20 °C Long-Term · Fridge Short-Term
Unmixed freeze-dried vials stay stable for months in the refrigerator and 1–2+ years at −20 °C (0 °F) in the dark. Let the vial warm to room temperature before opening.
Reconstituted Liquid (Mixed)
Refrigerate 2–8 °C (36–46 °F) · Use Within 30 Days
Keep refrigerated and out of light once mixed with bacteriostatic water. Never freeze reconstituted liquid — ice crystals shear the dissolved peptide chains.
Pharmacology & Evidence
How It Works
Binds amylin (AMY1R/AMY3R) and calcitonin receptors in the area postrema and nucleus tractus solitarius of the hindbrain, inducing non-incretin satiety signaling that complements GLP-1 receptor activation.
subcutaneous
0.6-2.4mg · Once weekly
16-68 weeks
subcutaneous
2.4-4.5mg · Once weekly
Maintenance
Research use only. Not medical advice.
Cagrilintide up to 4.5 mg weekly produced up to 10.8% weight loss at 26 weeks, exceeding liraglutide 3.0 mg
Phase 3 clinical development (Novo Nordisk), both as monotherapy and combined with semaglutide in CagriSema.
Clinical Profile
Provider Directory
Supplied as lyophilized powder in sterile multi-dose vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) and verify batch purity via HPLC and mass spectrometry COA.
Free Guide
New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.
Free. No spam. Unsubscribe anytime. From GLP1Search.
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.